Lupeol alters viability of SK-RC-45 (Renal cell carcinoma cell line) by modulating its mitochondrial dynamics

Krishnendu Sinha a, b, Sayantani Chowdhury b, Sharmista Banerjee b, Bhagirath Mandal c, Mullicka Mandal c, Sasadhar Majhi c, Goutam Brahmachari c, Jyotirmoy Ghosh d, Parames C. Sil b,*

a Department of Zoology, Jhargram Raj College, Jhargram, 721507, West Bengal, India
b Division of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII M, Kolkata, 700054, West Bengal, India
c Laboratory of Natural Products & Organic Synthesis, Department of Chemistry, Visva-Bharati University, Santiniketan, 731235, West Bengal, India
d Department of Chemistry, Banwarilal Bhalodia College, Asansol, 713303, West Bengal, India

ARTICLE INFO
Keyword:
Cancer research

ABSTRACT
Renal cell carcinoma (RCC) is the most common kidney cancer leading to 140,000 deaths per year. Among all RCCs 80% evolve from the epithelial proximal tubular cells within the kidney. There is a high tendency of developing chemoresistance and resistance to radiation therapy in most RCC patients. Therefore, kidney resection is considered as the most effective treatments for patients having localized RCC. There is a high tendency of post-operative recurrence among 20–40% of the patients and this recurrence is not curable. It is also clear that modern medicine has no curative treatment options against metastatic RCC. Lupeol [lup-20(29)-en-3β-ol] is a pentacyclic triterpenoid compound naturally found in various edible fruits and in many traditionally used medicinal plants, and has been demonstrated as effective against highly metastatic melanoma and prostate cancers. The present study was designed to evaluate the effect of lupeol to RCC with molecular details. Treatment with lupeol on SK-RC-45 (a RCC cell line) with the LC50 dose of 40 μM (for 48 h) induces mitochondrial hyperfi ssion which eventually leads to apoptosis while SK-RC-45 counteracts by enhancing autophagy-mediated selective removal of fragmented mitochondria. This is the first study which concurrently reports the effects of lupeol on RCC and its effect on the mitochondrial dynamics of a cell. Herein, we conclude that lupeol has potential to be an effective agent against RCC with the modulation of mitochondrial dynamics.

1. Introduction
Renal cell carcinoma (RCC) is the most common kidney cancer with over 350,000 cases reported annually, causing 140,000 deaths per year [1]. This cancer is reported to be the third leading cause of death for urological tumors [2]. Among various subtypes of RCC, the clear cell tumor subtype accounts for 80% of all RCCs. Epithelial proximal tubular cells are the origin place of this tumor within the kidney, with some instances also representing additional tubular origin [3]. RCC is a pervasive malignancy where one out of five patients having advanced stage already during diagnosis and 30% of the patients diagnosed with localized tumor develop metastases, even after removal of the parent tumor [3]. Once metastasis is reached, survival rate is 20% up to 5 years and average survival time is nearly one year [4]. Despite of various therapeutic options, proposed outcome of patients with locally advanced tumors or metastatic tumor remains poor [3]. There is a high tendency of developing chemoresistance and resistance to radiation therapy in most RCC patients. Therefore, kidney resection is considered to be the most effective treatments for patients having localized RCC [3]. The postoperative recurrence in RCC patients is around 20%–40% and it is rarely correctable [5]. Thus, there is an obvious necessity to advance treatment options for metastatic RCC [6]. Recently developed remedies targeting vascular endothelial growth factors, platelet growth factors, mammalian target of rapamycin, receptor tyrosine kinases have been reported to show comparatively longer progression-free survival with respect to standard care [7,8], however, the results are still far from being conclusive. For

* Corresponding author.
** Corresponding author.
E-mail addresses: brahmg2001@gmail.com, goutam.brahmachari@visva-bharati.ac.in (G. Brahmachari), parames@jcbose.ac.in, parames_95@yahoo.co.in (P.C. Sil).

https://doi.org/10.1016/j.heliyon.2019.e02107
Received 25 September 2018; Received in revised form 18 March 2019; Accepted 15 July 2019
2405-8440/© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
In this study we have investigated the effects of lupeol (Fig. 1a) on a RCC cell line, SK-RC-45. We have selected this particular cell line because these cells were generated from a human kidney cancer in the lining of the proximal convoluted tubule (PCT), the most common RCC [9].

The triterpene, lupeol [lup-20(29)-en-3β-ol] (Fig. 1a) is a “secondary metabolite” produced in various edible fruits such as strawberry, grapes, olive, mango, and figs as well as in many vegetables and medicinal plants [10]. Lupeol used in the study has been extracted from the barks of Bombax ceiba, an important medicinal plant finding many uses against many diseases manifestations such antimicrobial, wound healing, bone diseases, rheumatoid arthritis, joint pain and many more [11]. Lupeol has been found to possess numerous pharmaceutical activities (e.g. antioxidant, anti-inflammatory, antimutagenic) both in vitro and in vivo systems [12]. Researchers have shown that lupeol induces apoptosis in highly metastatic human pancreatic cancer cells such as AsPC-1 [13]. It has also been shown that Lupeol persuades differentiation of mouse melanoma cells [14]. Saleem et al. (2004) reported that Lupeol possesses significant antitumor activity in a two-stage model of mouse skin carcinogenesis [15]. According to their report, Lupeol was found to induce cell cycle arrest and apoptosis in metastatic melanoma cell line 451Lu cells [15].

Mitochondrial dynamics play a crucial role in cell survival and cell death mechanisms. Mitochondrial dynamics refers to the fusion and fission of mitochondria in the cellular milieu which leads to change of shape and morphology of mitochondria under various physiological as well as pathophysiological conditions. Mitochondrial fission is an well known phenomena in apoptosis The main machineries of fission are dynamin related protein (drp1), mitofusins 1,2 (Mfn 1, 2) and opa 1. The drp1 protein is a GTPase which moves back and forth from cytosol to outer mitochondria membrane of mitochondria under normal condition. Following cellular stress, pro-apoptotic bax and bak is activated. Bax and bak activation leads to sumoylation of drp1 and sumoylated drp1 gets stably attached with mitochondrial membrane. This drp1 assembles in a ring around mitochondria and breaks down the membrane [16]. Mitochondrial function and dynamics are regulated by bc1 family of proteins. This bc1 family proteins also influence wide array of cellular and mitochondrial activities like calcium balance, autophagy, mitophagy and bioenergetics [17]. In view of the wide range pharmacologic activities of Lupeol, here, we have shown that Lupeol has significant effect on the survival of SK-RC-45 which is further modulated by the autophagic process of SK-RC-45 cells in in-vitro model. Here, we suggest that Lupeol has the potential to be an effective agent against RCC with the modulation of mitochondrial dynamics [12].

2. Materials and methods

2.1. Materials and reagents

RPMI-1640 and fetal bovine serum (FBS) were bought from HIMEDIA (Mumbai, India) and HyClone (Thermo Scientific Hy-Clone, Logan, Utah). Methylthiazolyldiphenyl-tetrazolium bromide (MTT) was purchased from Sisco Research Laboratory (Mumbai, India). 3-MA was purchased from Sigma Aldrich (USA). Anti-Beclin-1, anti-LC3B-I/II, anti-Caspase-3 and HRP-tagged secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-β-actin, anti-β-tubulin, and HRP-tagged secondary antibodies were purchased from Sigma Aldrich (USA). Anti-Beclin-1, anti-LC3B-I/II, and HRP-tagged secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-β-actin, anti-β-tubulin, and HRP-tagged secondary antibodies were purchased from Sigma Aldrich (USA). 3-MA was purchased from Sigma Aldrich (USA). Mitochondrial morphometric parameters were evaluated by Fiji (Imagej v1.52e) using MiNA macro [20,21]. CLAHE, Median Filter and Tophat preprocessing had been applied to data images in MiNA analysis. These tools, and documentation regarding their usage, are available at https://github.com/ScienceToolkit/MiNA. The Fiji distribution of ImageJ on which the macros are designed to run is available at https://fiji.sc/.

2.2. Lupeol isolation

Lupeol was isolated from dried and powdered barks of Bombax ceiba as reported by Mukherjee and Roy [18], and verified based on its elemental analyses, physical and detailed spectral properties as described in results section.

2.3. Cell culture and treatment

Human Renal Cell Carcinoma (RCC) line, SK-RC-45 were used (obtained as a gift from Dr. Kausik Biswas, Bose Institute) for this study. The obtained cells were maintained in 75-cm² culture flasks at 37 °C in RPMI-1640 medium containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml gentamicine and 2.5 μg/ml amphotericin B in 5% CO₂ incubator. For the experimental purpose, Lupeol (filter-sterilized solution) treatment was done at the time of approximately 70% confluency. Lupeol was prepared following the protocol of Mutaza et al. (2009) [13]. Briefly, a stock solution of Lupeol (60 mM) was prepared in warm ethanol (47 °C). Then it was 5 times diluted in DMSO to get a of 12 mM and from it the working dilutions were prepared. The final concentrations of DMSO and alcohol were 0.25% and 0.075% in all the experiments [13]. The experiments were conducted under sterile conditions and the obtained experimental results were determined in triplicate. Lupeol treatment was done in RPMI-1640 media supplemented with 5% FBS.

2.4. Treatment of cells

A dose dependent study was carried out where SK-RC-45 cells were treated with 10–60 μM of Lupeol for 48 h along with one only vehicle treated group as control. The media was discarded after 48 h of treatment and the cells were washed twice with phosphate buffered saline (PBS) [19]. The LC₅₀ values and optimum time of Lupeol for SK-RC-45 was determined as 40μM and 48h. Cell lysates were prepared and stored at -80°C for later use.

2.5. Study of mitochondrial dynamics

Cells were grown and maintained on sterile glass cover slips following standard procedure [9]. After the incubation period with Lupeol (40μM), the cells were washed in PBS and replaced with pre warmed (37 °C) staining solution (serum free culture medium) containing MitoTracker® Deep Red FM probe at a concentration of 200nM. After incubation and treatment, SK-RC-45 cells were washed and the medium was replaced by the serum-free medium containing 200μM MitoTracker® Deep Red FM and incubated for 30 minutes under appropriate growth conditions. After staining was complete, cells were washed with PBS and fixed and mounted in VECTASHEILD Mounting Medium. All the slides were visualized under Leica TCS SP8. Mitochondrial morphometric parameters were evaluated by Fiji (Imagej v1.52e) using MiNA macro [20,21]. CLAHE, Median Filter and Tophat preprocessing had been applied to data images in MiNA analysis. These tools, and documentation regarding their usage, are available at https://github.com/ScienceToolkit/MiNA. The FIJI distribution of ImageJ on which the macros are designed to run is available at https://fiji.sc/.

2.6. Effects of autophagy inhibitors on cell viability

The cell viability was assessed with MTT assay. In briefly, 1 × 10⁵ cells were seeded into each well in 96-well culture plates. SK-RC-45 cells were treated with medium containing vehicle only (Control), 40μM of Lupeol, and 3-MA at a concentration of 5 mM respectively for 48 h. 3-MA was added to the medium 1 h prior to the addition of Lupeol. After incubation the cell viability was assessed by MTT assay described by Sinha et al. (2014) [9].

2.7. Cell lysis and immunoblotting

Cells were lysed with RIPA buffer supplemented with protease and phosphatase inhibitor. After addition of RIPA buffer, cells were vigorously vortexed and subjected to repeated freeze-thaw cycle followed by...
brief sonication. The lysates were centrifuged at 12,000 rpm at 4 °C for 10 min. The supernatant was collected and protein content was measured using Bradford reagent. For Western blot analysis, an equal amount of protein (50 μg) from respective experimental group was subjected to 10–12% SDS-PAGE and transferred to PVDF membranes. Nonspecific binding on the membrane was prevented by keeping the membrane in blocking buffer containing 5% BSA for 2 hours at room temperature. After blocking, the membranes were incubated with anti-Beclin-1 (1:1000 dilution) primary antibody at 4 °C overnight. The membranes were washed in TBST for 30 min followed by incubation with appropriate HRP-conjugated secondary antibody (1:15,000 dilution) for 2h at room temperature. Expression of proteins were detected using HRP substrate ECL solution.

2.8. Lupeol treatment on si-RNA mediated Bcl-2 knockdown cells

In brief, 1 day before transfection, 1.5 × 10⁵ cells were plated in 6 well plates in antibiotic free complete RPMI-1640. Transfection was done by 150 picomole siRNA (Bcl-2 or scramble) using 5μl of Lipofectamine-2000. 12 h post-transfection, 5 × 10⁴ cells were plated in a 12-well plate. These transfected cells were subjected to Lupeol treatment (i.e. 40 μM for 48 h). After treatment the viability was measured using MTT assay [19,22].

2.9. RNA extraction and reverse transcriptase PCR

RNA extraction and RT PCR was performed to confirm the silencing of bcl2 gene expression by si RNA treatment. RNA was extracted from cells with the help of TRIZOL reagent. Quantity of RNA was measured spectrophotometrically with the help of nanodrop HellmaTrayCell Type 105.810 (Hellma Analytical). One microgram of RNA was converted to cDNA with the help of Thermo Scientific Verso cDNA synthesis kit (Thermo Scientific, USA).

The thermal cycling was as follows: 95 °C for 5 min (initial denaturation) followed by the set of 35 cycles: 95 °C for 30 sec (denaturation), 55 °C for 30 sec (primer annealing), and 72 °C for 45 sec (primer extension). DNA extension step was done at 72°C for 5 min. The PCR products were held at 4 °C. The PCR products were resolved at 1.5% agarose gel. The details of the primer are: Bcl2 Forward: 5’GAGCACAGAAGATGGAACA 3’ Reverse: “CCACTGTCACTCTTG-CAATTIC”. GAPDH Forward “CCACCATTTGTCAGCTCA” Reverse: “TTCCTCTTGTGCTCTTGCTG”

2.10. Detection of cell death by annexin V affinity assay

SK-RC-45 cells were treated as per described in the method section previously. The cells were scraped and centrifuged at 300g for 5 min at room temperature at the end of respective incubation time (Sinha et al., 2014). The pellets were collected and washed with PBS. After PBS wash, in 1X Annexin V Binding Buffer was used to resuspend the pellets followed by incubation for 5 mins in dark with 1μl of Annexin V/at RT. The samples were then analyzed at FACS Verse with an excitation at 488 nm and emission at 520 nm respectively using the FACSuite software.

2.11. Statistical analysis

Results are expressed as mean (±SEM) from three independent experiments. Statistical evaluation were done with the help of means of one-way analysis of variance (ANOVA) and the group means were compared through Tukey test. p-value less than 0.05 were considered as statistically significant.

3. Results

3.1. Isolation of lupeol

Isolated Lupeol was verified based on its elemental analyses, physical and spectral properties as described: white microcrystalline powder; mp
205–207 °C; IR (KBr): v_{max} = 3325 (OH), 3068, 1637, 1032, 881 cm\(^{-1}\). 
\(^1\)H NMR (400 MHz, CDCl3): δ = 0.69-0.67 (m, 1 H, H-5), 0.76 (s, 3 H, H-23), 0.78 (s, 3 H, H-24), 0.83 (s, 3 H, H-25), 0.90-0.86 (m, 1 H, H-1a), 0.94 (s, 3 H, H-26), 0.96 (s, 3 H, H-27), 1.03 (s, 3 H, H-28), 1.11-1.05 (m, 1 H, H-1b), 1.23-1.16 (m, 2 H, H-22), 1.26-1.25 (m, 2 H, H-21), 1.29-1.28 (m, 1 H, H-11b), 1.33-1.31 (m, 1 H, H-9), 1.36-1.35 (m, 1 H, H-1b), 1.39-1.37 (m, 1 H, H-11a), 1.39-1.37 (m, 1 H, H-18), 1.39-1.37 (m, 1 H, H-9), 1.45-1.40 (m, 2 H, H-7), 1.57-1.48 (m, 2 H, H-16), 1.60-1.58 (m, 2 H, H-15), 1.60-1.58 (m, 1 H, H-13), 1.65-1.62 (m, 2 H, H-2), 1.68 (s, 3 H, H-30), 2.00-1.88 (m, 1 H, H-12a), 2.41-2.34 (m, 1 H, H-19), 3.19-3.17 (m, 1 H, H-3), 4.57-4.56 (m, 1 H, H-29b), 4.68 (d, J = 2.4 Hz, 1 H, H-29a) ppm. \(^{13}\)C NMR (100 MHz, CDCl3): δ = 14.69 (C-27), 15.51 (C-24), 16.12 (C-26), 16.27 (C-25), 18.15 (C-28), 18.47 (C-6), 19.45 (C-30), 21.08 (C-11), 25.30 (C-12), 27.56 (C-15), 27.60 (C-23), 28.14 (C-2), 30.00 (C-21), 34.44 (C-16), 35.74 (C-7), 37.32 (C-10), 38.20 (C-13), 38.86 (C-1), 39.01 (C-4), 40.15 (C-22), 40.99 (C-8), 42.98 (C-17), 43.15 (C-14), 48.13 (C-18), 48.45 (C-19), 50.59 (C-9), 55.45 (C-5), 79.16 (C-3), 109.46 (C-29), 151.12 (C-20) ppm. HRESIMS: m/z 449.3751 [M + Na]\(^+\) (Cald. for C\(_{26}\)H\(_{50}\)O\(_{6}\)Na at m/z 449.3759). Elemental analysis: calcd (%) for C\(_{30}\)H\(_{50}\)O\(_{6}\): C, 84.44; H, 11.81; Found: C, 84.48; H, 11.79.

3.2. Dose and time dependent effect of lupeol on SK-RC-45

Fig. 1b shows the dose dependent effect of Lupeol on SK-RC-45. We observed an approximately two fold decrease in cell viability upon 40μM Lupeol treatment over 48 h. Hence, the dose of 40μM for 48 h was found to be the LC\(_{50}\) of Lupeol for SK-RC-45. We used this LD\(_{50}\) dose and a lower less effective dose (20μM) for further experimentations to observe progressive dose dependent changes. We also found a significant increase over control in caspase-3 cleavage at these doses [Fig. 1c, Fig S1(c) supplementary figure]. Apoptosis was also confirmed through annexin-V/FTTC binding assay with the help of flowcytometry (Fig. 1d).

3.3. Lupeol induces mitochondrial fission in SK-RC-45

Fig. 2a shows the architecture of mitochondrial network and status of mitochondrial dynamics at the specific time point. For this purpose we extract four vital information from the images namely Networks, Mean Length, Mean Network Size and Mitochondrial Footprint (Fig. 2). We observed dose dependent significant decrease of all these four parameters in Lupeol treated cells, in respect to control (Fig. 2b-e). In this respect we were also interested to investigate the effect of Bcl-2 in the whole process as we know that this anti-apoptotic protein have significant effect on the mitochondrial dynamics. Fig. 2f shows that the Bcl-2 knock down significantly increased the efficacy of Lupeol's effect on SK-RC-45 [Fig S2(g); supplementary figure], RT PCR data confirms the knockdown of Bcl2 gene using siRNA in SKRC45 cell line.

3.4. SK-RC-45 alienates the effect of lupeol by inducing autophagy

Fig. 3a, Fig S3 (a) supplementary figure shows the status of autophagy in Lupeol treated SK-RC-45 cells. We observed significant increase of autophagic cellular markers, Beclin-1 and LC3B II in a dose dependent manner. We also found that, over the same experimental conditions, cellular survivality significantly decreased upon inhibition of autophagy (Fig. 3b). This signifies that autophagy was initiated by cells (not by...
Lupeol (20 μM): 40 μM Lupeol treatment for 48 h; (a) Immunoblot analysis of Beclin-1 and LC-3B I/II from whole lysate of SK-RC-45 from all three groups. Note that, upon Lupeol treatment cellular Beclin-1 and LC-3B II level (thus promotes LC-3B I to LC-3B II conversion) increased. (b) Effect of 3-MA pretreatment on Lupeol treatment. Note that, upon 3-MA pre-treatment cell death significantly induced upon Lupeol treatment in respect to Lupeol treatment alone. Here Lupeol was used at a dose of 40 μM for 48 h *P < 0.05 vs. Control.

4. Discussion

In this study, we have established that (1) the administration of Lupeol significantly reduces the viability of RCC cell SK-RC-45; (2) it alters the mitochondrial dynamics by inducing mitochondrial fission which sequentially leads to apoptosis; (3) cell alienates the process by inducing autophagy response probably with an aim to remove fragmented mitochondrial copies.

The triterpene, Lupeol has already been found to possess anticancer effect and tested over several types of cancers. But its effect on RCC was unknown. Here in this study we have found that Lupeol have profound effect and tested over several types of cancers. But its effect on RCC was unknown. Here in this study we have found that Lupeol have profound effect and tested over several types of cancers. In our quest, we found that autophagy was induced upon Lupeol treatment (Fig. 3b). This signifies the protective effect of autophagy upon Lupeol treatment.

It is well known that Bcl-2 have a pro-survival anti-apoptotic role. On mitochondrial outer membrane it also form heterodimer with Bax, a pro-apoptotic protein and a prominent mitochondrial fission inducer [16,28,29,30]. So it can be easily postulated that in the absence of Bcl-2 would augment the mitochondrial fission and cell death. From our study we also found the same result. We found that Bcl-2 knock down augment the effect of Lupeol thus, mitochondrial fission and cell death (Fig. 2f).

Therefore, the outcome of the study indicates that, Lupeol induces mitochondrial hyper fission which ultimately leads to apoptosis. Cell tries to protect itself by augmenting autophagy mediated selective removal of fragmented mitochondria which is also evident from the loss of mitochondrial footprint upon Lupeol exposure. The study is one of its kind as it is the first report showing the excellent pharmacological effects of Lupeol against the RCC and also the first to report the effect of Lupeol on the mitochondrial dynamics of a cell.

Declarations

Author contribution statement

Parames C. Sil, Goutam Brahmachari: Conceived and designed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Krishnendu Sinha, Sayantani Chowdhury, Sharmistha Banerjee: Performed the experiments; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Mullicka Mandal: Contributed reagents, materials, analysis tools or data; Wrote the paper.

Jyotirmoy Ghosh: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.

Funding statement

This work was supported by the Council of Scientific & Industrial Research, New Delhi who provided G. Brahmachari with a financial grant [No. 02(0260)/2016/EMR-II], and the University Grant Commission Minor Research Project who provided financial support to Jyotirmoy Ghosh [No. F.PSW-014/15-16(ERO)].

Competing interest statement

The authors declare no conflict of interest.
Additional information

Supplementary content related to this article has been published online at https://doi.org/10.1016/j.heliyon.2019.e02107.

Acknowledgements

Krishnendu Sinha acknowledges Jhargram Raj College for its kind cooperation to complete the study and all the authors are grateful to Sayanta Dutta for his assistance in FACS experiment.

References

[1] V. Kumar, A.K. Abbasi, N. Fausto, J.C. Aster, Robbins and Cotran pathologic basis of disease, professional edition e-book, elsevier health sciences, 2014.
[2] J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet], 2, International Agency for Research on Cancer, Lyon, France, 2010.
[3] M. Babjerg, Identification and validation of novel prognostic, Danish Medical Journal 64 (2017) pii: B5339.
[4] L. Buvall, H. Hedman, A. Khramova, D. Najar, L. Bergwall, K. Ebefors, C. Sihlbom, C.-R. Yeh, Z.-Y. Ou, G.-Q. Xiao, E. Guancial, S. Yeh, In cell carcinoma, Oncotarget 8 (2017) 91085–91107.
[5] A.J. Valente, L.A. Maddalena, E.L. Robb, F. Moradi, J.A. Stuart, A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture, Acta Histochem. 119 (2017) 315–326.
[6] M. Liesa, M. Palacín, A. Zorzano, Mitochondrial dynamics in mammalian health and disease, Physiol. Rev. 89 (2009) 799–845.
[7] J.K. Coon, Z. Liu, M. Hoyle, G. Rogers, C. Green, T. Moxham, K. Welch, K. Stein, Sunnihilb and bevaccimab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness, Br. J. Canc. 101 (2009) 238–243.
[8] D. Gi Lorenzo, C. Buonerba, M. Biglietto, F. Scognamiglio, B. Chiurazzi, F. Riccardi, G. Carteni, The therapy of kidney cancer with biomolecular drugs, Cancer Treat. Rev. 36 (2010) S16–S20.
[9] K. Sinha, P.B. Pal, P.C. Sil, Cadmium (Cd2+) exposure differentially elicits both cell proliferation and cell death related responses in SK-RC-45, Toxicol. In Vitro 28 (2014) 307–318.
[10] M. Saleem, N. Maddodi, M.A. Zaid, N. Khan, B. bin Hafeez, M. Asim, Y. Suh, J.-M. Yun, V. Setaluri, H. Mukhtar, Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis, Clin. Cancer Res. 14 (2008) 2119–2127.
[11] K. Sinha, P.B. Pal, P.C. Sil, Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis, Arch. Toxicol. 87 (2013) 1157–1180.
[12] M. Saleem, M.-H. Kweon, J.-M. Yun, V.M. Adhami, N. Khan, D.N. Syed, H. Mukhtar, A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model, Cancer Res. 65 (2005) 11203–11213.
[13] I.M. Murtaza, M. Saleem, V.M. Adhami, B.B. Hafeez, H. Mukhtar, Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells, Cancer Res. 69 (2009) 1156–1165.
[14] M. Saleem, F. Afag, V.M. Adhami, H. Mukhtar, Lupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice, Oncogene 23 (2004) 5203–5214.
[15] J.C. Martinou, R.J. Youle, Mitochondria in apoptosis: bcl-2 family members and mitochondrial dynamics, Dev. Cell 21 (2011) 92–101.
[16] A. Aosacheria, S. Bagdhigian, H.M. Lamb, J.D. Hanks, F.J. Pineda, J.M. Hardwick, Connecting mitochondrial dynamics and life-or-death events via Bcl-2 family proteins, Neurochem. Int. 109 (2017) 141–161.
[17] M. Saleem, F. Afag, V.M. Adhami, H. Mukhtar, Lupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice, Oncogene 23 (2004) 5203–5214.
[18] J. Mukherjee, B. Roy, Chemical Examination of Salmalia Malabarica Schott & Endl. Syn. bombax Malabaricum Dc, Indian Chem Soc J, 1971.
[19] M. Madesh, K. Balasubramanian, A microtiter plate assay for superoxide using MTT reduction method, Indian J. Biochem. Biophys. 34 (1997) 535–539.
[20] A.J. Valente, L.A. Maddalena, E.L. Robb, F. Moradi, J.A. Stuart, A simple ImageJ macro tool for analyzing mitochondrial network morphology in mammalian cell culture, Acta Histochem. 119 (2017) 315–326.
[21] E.F. Iannetti, J.A. Smeitink, J. Beyrath, P.H. Willems, W.J. Koopman, Multiplexed high-content analysis of mitochondrial morphofunction using live-cell microscopy, Nat. Protoc. 11 (2016) 1693–1710.
[22] B. Mahata, A. Banerjee, M. Kundu, U. Bandyopadhyay, K. Biswas, TALEN mediated targeted editing of GM2/GD2-synthase gene modulates anchorage independent growth by reducing anoikis resistance in mouse tumor cells, Sci. Rep. 5 (2015) 9048.
[23] J.R. Youle, M. Karbowski, Mitochondrial fission in apoptosis, Nat. Rev. Mol. Cell Biol. 6 (2005) 657–663.
[24] M. Liesa, M. Palacín, A. Zorzano, Mitochondrial dynamics in mammalian health and disease, Physiol. Rev. 89 (2009) 799–845.
[25] S.A. Detmer, D.C. Chan, Functions and dysfunctions of mitochondrial dynamics, Nat. Rev. Mol. Cell Biol. 8 (2007) 876–879.
[26] D.J. Suen, K.L. Norris, R.J. Youle, Mitochondrial dynamics, Dev. Cell 21 (2011) 92–101.
[27] E.F. Iannetti, J.A. Smeitink, J. Beyrath, P.H. Willems, W.J. Koopman, Multiplexed high-content analysis of mitochondrial morphofunction using live-cell microscopy, Nat. Protoc. 11 (2016) 1693–1710.
[28] G. Twig, A. Elorza, A.J. Molina, H. Mohamed, J.D. Huska, F.J. Pineda, J.M. Hardwick, Connecting mitochondrial dynamics and life-or-death events via Bcl-2 family proteins, Neurochem. Int. 109 (2017) 141–161.
[29] M. Saleem, F. Afag, V.M. Adhami, H. Mukhtar, Lupeol modulates NF-κB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice, Oncogene 23 (2004) 5203–5214.